CLINICAL_TRIALS
trial_result
· 2014-07-03
Clinical Trial Update: A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder [Phase 2]
Summary
A 12-week, placebo-controlled Phase 2 trial evaluating ziprasidone as monotherapy for major depressive disorder has completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2014-07-03